Literature DB >> 26455458

Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease.

Fabio A Zucca1, Juan Segura-Aguilar2, Emanuele Ferrari1, Patricia Muñoz2, Irmgard Paris3, David Sulzer4, Tadeusz Sarna5, Luigi Casella6, Luigi Zecca7.   

Abstract

There are several interrelated mechanisms involving iron, dopamine, and neuromelanin in neurons. Neuromelanin accumulates during aging and is the catecholamine-derived pigment of the dopamine neurons of the substantia nigra and norepinephrine neurons of the locus coeruleus, the two neuronal populations most targeted in Parkinson's disease. Many cellular redox reactions rely on iron, however an altered distribution of reactive iron is cytotoxic. In fact, increased levels of iron in the brain of Parkinson's disease patients are present. Dopamine accumulation can induce neuronal death; however, excess dopamine can be removed by converting it into a stable compound like neuromelanin, and this process rescues the cell. Interestingly, the main iron compound in dopamine and norepinephrine neurons is the neuromelanin-iron complex, since neuromelanin is an effective metal chelator. Neuromelanin serves to trap iron and provide neuronal protection from oxidative stress. This equilibrium between iron, dopamine, and neuromelanin is crucial for cell homeostasis and in some cellular circumstances can be disrupted. Indeed, when neuromelanin-containing organelles accumulate high load of toxins and iron during aging a neurodegenerative process can be triggered. In addition, neuromelanin released by degenerating neurons activates microglia and the latter cause neurons death with further release of neuromelanin, then starting a self-propelling mechanism of neuroinflammation and neurodegeneration. Considering the above issues, age-related accumulation of neuromelanin in dopamine neurons shows an interesting link between aging and neurodegeneration.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Dopamine; Human neuromelanin; Iron; Melanin; Parkinson's disease

Mesh:

Substances:

Year:  2015        PMID: 26455458      PMCID: PMC4826627          DOI: 10.1016/j.pneurobio.2015.09.012

Source DB:  PubMed          Journal:  Prog Neurobiol        ISSN: 0301-0082            Impact factor:   11.685


  316 in total

Review 1.  The physical and chemical properties of eumelanin.

Authors:  Paul Meredith; Tadeusz Sarna
Journal:  Pigment Cell Res       Date:  2006-12

2.  Role of semiconductivity and ion transport in the electrical conduction of melanin.

Authors:  Albertus B Mostert; Benjamin J Powell; Francis L Pratt; Graeme R Hanson; Tadeusz Sarna; Ian R Gentle; Paul Meredith
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-21       Impact factor: 11.205

3.  Binding of iron to neuromelanin of human substantia nigra and synthetic melanin: an electron paramagnetic resonance spectroscopy study.

Authors:  T Shima; T Sarna; H M Swartz; A Stroppolo; R Gerbasi; L Zecca
Journal:  Free Radic Biol Med       Date:  1997       Impact factor: 7.376

Review 4.  Aromatic rings in chemical and biological recognition: energetics and structures.

Authors:  Laura M Salonen; Manuel Ellermann; François Diederich
Journal:  Angew Chem Int Ed Engl       Date:  2011-04-28       Impact factor: 15.336

5.  Protein carbonyl groups as biomarkers of oxidative stress.

Authors:  Isabella Dalle-Donne; Ranieri Rossi; Daniela Giustarini; Aldo Milzani; Roberto Colombo
Journal:  Clin Chim Acta       Date:  2003-03       Impact factor: 3.786

6.  Structural characteristics of human substantia nigra neuromelanin and synthetic dopamine melanins.

Authors:  K L Double; L Zecca; P Costi; M Mauer; C Griesinger; S Ito; D Ben-Shachar; G Bringmann; R G Fariello; P Riederer; M Gerlach
Journal:  J Neurochem       Date:  2000-12       Impact factor: 5.372

Review 7.  Binding of dopaminergic drugs by the neuromelanin of the substantia nigra, synthetic melanins and melanin granules.

Authors:  M Salazar; T D Sokoloski; P N Patil
Journal:  Fed Proc       Date:  1978-08

8.  The effect of cysteine on oxidation of tyrosine, dopa, and cysteinyldopas.

Authors:  G Agrup; C Hansson; H Rorsman; E Rosengren
Journal:  Arch Dermatol Res       Date:  1982       Impact factor: 3.017

9.  Identification and quantification of dolichol and dolichoic acid in neuromelanin from substantia nigra of the human brain.

Authors:  Weslyn C Ward; Ziqiang Guan; Fabio A Zucca; Ruggero G Fariello; Reza Kordestani; Luigi Zecca; Christian R H Raetz; John D Simon
Journal:  J Lipid Res       Date:  2007-04-19       Impact factor: 5.922

10.  MHC-I expression renders catecholaminergic neurons susceptible to T-cell-mediated degeneration.

Authors:  Carolina Cebrián; Fabio A Zucca; Pierluigi Mauri; Julius A Steinbeck; Lorenz Studer; Clemens R Scherzer; Ellen Kanter; Sadna Budhu; Jonathan Mandelbaum; Jean P Vonsattel; Luigi Zecca; John D Loike; David Sulzer
Journal:  Nat Commun       Date:  2014-04-16       Impact factor: 14.919

View more
  177 in total

Review 1.  Neurotoxins as Preclinical Models for Parkinson's Disease.

Authors:  Juan Segura-Aguilar
Journal:  Neurotox Res       Date:  2018-01-08       Impact factor: 3.911

2.  Quantitative magnetization transfer imaging of the human locus coeruleus.

Authors:  Paula Trujillo; Kalen J Petersen; Matthew J Cronin; Ya-Chen Lin; Hakmook Kang; Manus J Donahue; Seth A Smith; Daniel O Claassen
Journal:  Neuroimage       Date:  2019-06-21       Impact factor: 6.556

3.  Imaging of neuronal tissues by x-ray diffraction and x-ray fluorescence microscopy: evaluation of contrast and biomarkers for neurodegenerative diseases.

Authors:  Eleonora Carboni; Jan-David Nicolas; Mareike Töpperwien; Christine Stadelmann-Nessler; Paul Lingor; Tim Salditt
Journal:  Biomed Opt Express       Date:  2017-09-05       Impact factor: 3.732

Review 4.  Neurotoxicity Linked to Dysfunctional Metal Ion Homeostasis and Xenobiotic Metal Exposure: Redox Signaling and Oxidative Stress.

Authors:  Carla Garza-Lombó; Yanahi Posadas; Liliana Quintanar; María E Gonsebatt; Rodrigo Franco
Journal:  Antioxid Redox Signal       Date:  2018-03-28       Impact factor: 8.401

5.  Relationship between neuromelanin and dopamine terminals within the Parkinson's nigrostriatal system.

Authors:  Antonio Martín-Bastida; Nicholas P Lao-Kaim; Andreas Antonios Roussakis; Graham E Searle; Yue Xing; Roger N Gunn; Stefan T Schwarz; Roger A Barker; Dorothee P Auer; Paola Piccini
Journal:  Brain       Date:  2019-07-01       Impact factor: 13.501

Review 6.  The delta-opioid receptor and Parkinson's disease.

Authors:  Jin-Zhong Huang; Yi Ren; Yuan Xu; Tao Chen; Terry C Xia; Zhuo-Ri Li; Jian-Nong Zhao; Fei Hua; Shi-Ying Sheng; Ying Xia
Journal:  CNS Neurosci Ther       Date:  2018-08-03       Impact factor: 5.243

Review 7.  Neuroinflammation in L-DOPA-induced dyskinesia: beyond the immune function.

Authors:  Augusta Pisanu; Laura Boi; Giovanna Mulas; Saturnino Spiga; Sandro Fenu; Anna R Carta
Journal:  J Neural Transm (Vienna)       Date:  2018-03-14       Impact factor: 3.575

8.  Neuromelanin organelles are specialized autolysosomes that accumulate undegraded proteins and lipids in aging human brain and are likely involved in Parkinson's disease.

Authors:  Fabio A Zucca; Renzo Vanna; Francesca A Cupaioli; Chiara Bellei; Antonella De Palma; Dario Di Silvestre; Pierluigi Mauri; Sara Grassi; Alessandro Prinetti; Luigi Casella; David Sulzer; Luigi Zecca
Journal:  NPJ Parkinsons Dis       Date:  2018-06-05

9.  Promoting Endothelial Cell Affinity and Antithrombogenicity of Polytetrafluoroethylene (PTFE) by Mussel-Inspired Modification and RGD/Heparin Grafting.

Authors:  Hao-Yang Mi; Xin Jing; James A Thomsom; Lih-Sheng Turng
Journal:  J Mater Chem B       Date:  2018-05-09       Impact factor: 6.331

10.  Dentate nucleus iron deposition is a potential biomarker for tremor-dominant Parkinson's disease.

Authors:  Naying He; Pei Huang; Huawei Ling; Jason Langley; Chunlei Liu; Bei Ding; Juan Huang; Hongmin Xu; Yong Zhang; Zhongping Zhang; Xiaoping Hu; Shengdi Chen; Fuhua Yan
Journal:  NMR Biomed       Date:  2016-05-18       Impact factor: 4.044

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.